Novo Nordisk reports interim results from late-stage trial of its haemophilia A treatment
Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...
The Pharma Letter3h
Novo Nordisk adds to Mim8 data set ahead of filing
Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...
PMLiVE4h
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...
ENDPOINTS NEWS4h
No­vo Nordisk takes aim at Roche in he­mo­phil­ia A, but is way be­hind
Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.
FierceBiotech7h
Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
Euroinvestor8h
Novo Nordisk med nye resultater på hæmofili-medicin
Novo Nordisk er kommet med friske resultater fra et fase 3-studie med 70 børn med selskabets nye middel Mim8 mod hæmofili, ...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...
PipelineReview.com9h
Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...
Hosted on MSN13h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Hematology and Immunology Strategic Portfolio Supports Sobi's Narrow Moat
Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...